Effect of Heat Stress on Global LV Function in Anesthetized Humans

September 17, 2020 updated by: Edward O'Brien, University of California, San Diego
Recent data suggests that increased temperature improves inotropic function during systole and may improve diastolic function in healthy humans at rest, despite a reduction in left ventricular volume at end diastole. The effect of heat stress has not been reported in patients receiving general anesthesia and the impact of general anesthesia on these findings is not known. Trans-esophageal echocardiography will be used to measure parameters important to both systolic and diastolic function at temperature intervals of 1°C in patients undergoing "Heated Intraoperative Peritoneal Chemotherapy" (HIPEC.) That general anesthesia will not alter the cardiovascular effects of increased temperature that has been reported in healthy, un-anesthetized humans is the hypothesis.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • La Jolla, California, United States, 92093
        • University of California, San Diego

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • any patient presenting for hyperthermic intraperitoneal chemotherapy.

Exclusion Criteria:

  • Subjects less than 18 years old.
  • pregnant women
  • prisoners,
  • institutionalized individuals
  • Any patient with known contraindication to Transesophageal echocardiography.
  • Patients with known cardiac dysfunction prior to screening will be excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in ejection fraction before and after hyperthermia
Time Frame: Approximately 6 hours from prior to hyperthermia to during hyperthermia.
Approximately 6 hours from prior to hyperthermia to during hyperthermia.

Secondary Outcome Measures

Outcome Measure
Time Frame
Transmitral inflow velocities before and after hyperthermia
Time Frame: Approximately 6 hours from prior to hyperthermia to during hyperthermia.
Approximately 6 hours from prior to hyperthermia to during hyperthermia.
Pulmonary venous inflow velocities before and during hyperthermia
Time Frame: Approximately 6 hours from prior to hyperthermia to during hyperthermia.
Approximately 6 hours from prior to hyperthermia to during hyperthermia.
Mitral annular tissue doppler velocities before and during hyperthermia
Time Frame: Approximately 6 hours from prior to hyperthermia to during hyperthermia.
Approximately 6 hours from prior to hyperthermia to during hyperthermia.

Other Outcome Measures

Outcome Measure
Time Frame
heart rate before and during hyperthermia
Time Frame: Approximately 6 hours from prior to hyperthermia to during hyperthermia.
Approximately 6 hours from prior to hyperthermia to during hyperthermia.
mean arterial pressure before and during hyperthermia
Time Frame: Approximately 6 hours from prior to hyperthermia to during hyperthermia.
Approximately 6 hours from prior to hyperthermia to during hyperthermia.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of California, San Diego

Investigators

  • Principal Investigator: Edward O O'Brien, MD, University of California, San Diego

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 9, 2017

Primary Completion (Actual)

December 6, 2019

Study Completion (Actual)

December 6, 2019

Study Registration Dates

First Submitted

September 11, 2020

First Submitted That Met QC Criteria

September 11, 2020

First Posted (Actual)

September 18, 2020

Study Record Updates

Last Update Posted (Actual)

September 21, 2020

Last Update Submitted That Met QC Criteria

September 17, 2020

Last Verified

September 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 171159

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperthermia

Clinical Trials on Transesophageal Echocardiography

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe